Latest news with #Doxorubicin
The Courier
3 days ago
- Health
- The Courier
Why Dundee mum with incurable breast cancer is determined to keep fighting for her son
Kim Anderson recently conquered the UK's highest peak – ticking another goal off her bucket list. Climbing Ben Nevis is an incredible feat for anyone to achieve. But it proved to be even more poignant for the young mum from Dundee because she is battling incurable secondary breast cancer. 'I still can't believe I did it!,' Kim, 38, says. 'It took me 15 hours in total. 'I am just so happy I completed it because I wasn't sure I would manage. 'It just goes to show you can do anything you put your mind to.' Kim was first diagnosed with breast cancer six years ago. She underwent treatment which was successful. But two years ago the mum-of-one started feeling unwell and a CT scan revealed the cancer had returned. This time it has spread to other parts of her body including her brain. But Kim wants to show that a diagnosis of secondary breast cancer doesn't mean your life is immediately over. She is determined to live as long as she can to see her young son grow up. In 2019 Kim, who was then aged 32, recalls showering one morning when she felt something unusual. 'I felt this huge lump on my left breast which I hadn't felt before,' she explains. 'I was a bit shocked but I called the doctor straight away. 'The doctor examined me and said it was likely just a cyst. 'She said I was too young to have cancer. 'She referred me to the breast clinic anyway but said it would be nothing to worry about.' In August 2019 Kim attended the breast clinic at Ninewells Hospital in Dundee. She had a mammogram, along with other tests. Kim took her young son Bobby, who was only eight, with her. 'That's how unbothered by it I was. I thought I would be there for a quick look and then away again,' she explains. As she was there longer she got her sister to pick up her son. Kim then had a biopsy taken and an ultrasound. 'A consultant came in, took my hand and told me I was in the right place,' she continues. 'And I said to him: 'The right place for what?' 'He replied: 'Has no-one spoken to you yet?' I said 'no'. So he went to get one of the nurses. 'And I was taken into a private room. 'That's when they told me I had breast cancer. 'I felt like my stomach fell through the floor. 'I couldn't believe what I was hearing – I had no inkling of it.' Kim was told she had HER2-positive breast cancer and that it was stage three. It was quite far advanced and aggressive. But it hadn't spread to other parts of her body. In that moment all Kim could think about was her young son. 'I was a single mum at the time and I just thought how am I going to tell him? 'How will we manage?' Kim then went home and told her sister. 'I then Facetimed my mum, Julia, who lives in Texas and she couldn't believe it. None of us could.' A few weeks later in October 2019 Kim started her cancer treatment. She was given so-called 'Red Devil chemotherapy' – a nickname for the chemotherapy drug Doxorubicin known for its harsh side effects. Kim had six rounds of this chemotherapy at Ninewells which finished in January 2020. Then before she had a course of radiotherapy Kim had a mastectomy with reconstruction. In February 2020 Kim had a follow-up appointment at the breast clinic. 'My doctor told me I was cancer free and that I should go and live my life. 'I was so relieved and wanted to do exactly that.' After life got back to normal after the pandemic Kim took Bobby to America to spend time with her mum. 'I just grabbed the opportunity because I thought you only live once.' But in May 2023 Kim started to feel unwell. 'I had a continuous cough and was completely exhausted,' she says. 'I went to the doctor's but was told it was just health anxiety because of what I had been through before. 'But I knew something was wrong. I had also lost a lot of weight.' A few months later in September Kim was struggling to breathe so her partner Mark took her to Ninewells. She had a CT scan. 'The next morning a woman from the hospital phoned me with the results,' Kim says. 'She told me they had found cancer in a lot of places in my body. 'My head started spinning. 'She said it looked like secondary breast cancer which had metastasised in other areas including my throat. 'I was in an absolute state and just kept saying to Mark 'I'm going to die'.' Doctors discovered a 5cm tumour in Kim's throat so she had radiotherapy straight away to shrink it. She then had a further 12 weeks of chemotherapy before having maintenance treatment. 'I was told the cancer is now incurable. 'But they would be able to keep it at bay with treatment.' The aim of treatment for someone with secondary breast cancer is to slow down the spread of the disease. This can help someone live a normal life for many years. Scans also revealed she had a 3cm tumour in her brain. 'When I learned it had gone to my brain I just thought I'm screwed. 'But the nurses helped me to get into a more positive mindset. 'They told me there were still lots of treatments to try.' In September 2024 Kim had surgery to remove the tumour which was a success. She has now been on her current maintenance treatment for two months. Kim is grateful to have the support of her family. 'My mum has been flying over from Texas every time there has been a crisis or a treatment change. 'She helps me around the house when I am unwell. My sisters have been great too. 'Mark has also been really supportive. 'He has been by my side at every hospital appointment.' Kim has a few things on her bucket list including travelling the North Coast 500. She is also organising a fundraising event on October 25 at Mains Castle in Dundee – with plans to split the money raised between the charity Make 2nds Count and a savings account for Bobby. But her main focus is to be around to see her 14-year-old son, who attends St John's RC High, grow up. 'I don't want to leave him here without a mum when he's a child. And that really is my driving force. 'He says to me: 'Mum you can't leave me here, you have to fight this'. 'And I tell him I am doing it – with as much fight as I have got in me I will use it to stay with him.' Kim is also passionate about raising awareness of secondary breast cancer. 'You can still live. You can still do things and look after yourself as best you can. 'Of course there are days you want to stay in your bed – but just don't stay there.' She adds: 'My biggest reason to keep on fighting is my son – he is the one who needs me most.'
Hans India
3 days ago
- Health
- Hans India
Patanjali study highlights the effectiveness of Cardiogrit Gold
Haridwar: Patanjali has once again demonstrated the impressive synergy between Ayurveda and modern sci-ence, showing that even the most challenging diseases can find relief through traditional methods. A study conducted by Patanjali highlights the effectiveness of Cardiogrit Gold, a novel herbo-mineral medicine developed by Patanjali's dedicated scientists, in reducing cardiotoxicity associated with the widely used chemotherapy drug Doxorubicin. On this occasion, Acharya Balkrishna stated that this groundbreaking research not only validates the scientific foundations of Ayurveda on a global scale but also illustrates how rigorous examination of traditional medicine can help address some of modern medicine's most complex challenges. Cardiogrit Gold combines a range of natural ingredients, including Yogendra Ras, Arjun, Moti Pishti, Akik Pishti, and others, all of which are honoured in ancient Ayurvedic texts for their beneficial effects on heart health. He further expressed that this achievement is a testament to the relentless dedication of Patanjali's scientists and represents the revival of India's timeless medical heritage, Ayurveda. As global interest in Ayurveda surges, Patanjali's research reinforces the importance of combining traditional wisdom with scientific validation. This study not only revitalises Ayurveda but also highlights its potential to offer novel, holistic solutions for contemporary health challenges. In this pioneering study using the C. elegans model, Cardiogrit Gold was found to increase food in-take, improve cardiac muscle health, and significantly reduce reactive oxygen species (ROS) lev-els. Remarkably, these organisms showed a significant increase in body length and fertility, high-lighting the systemic benefits of the formulation. Additionally, Cardiogrit Gold effectively re-duced Doxorubicin accumulation, further underscoring its potential to mitigate cardiotoxic effects. This groundbreaking research has been published in the prestigious Journal of Toxicology by Wiley Publications, marking a significant milestone in integrative medicine.
Time of India
28-06-2025
- Health
- Time of India
Cardiologist says these 5 common medicines could harm your heart without any warning
Medicines are meant to heal—but what good are they if they cure one problem while quietly creating another? Many drugs we rely on for everyday aches, colds, or chronic conditions have been around for years and are often trusted without a second thought. But just because something is familiar doesn't mean it's completely safe. In fact, some commonly used medications might be doing more harm than we realize—especially to the heart. In a recent Instagram post, cardiologist Dr. Dmitry Yaranov sounded the alarm on five widely used drugs that could potentially harm your heart without clear warning signs. 'As a cardiologist, I see how some commonly used medications can silently damage your heart,' he wrote, urging patients to stay informed and proactive. Here are the five medications Dr. Yaranov cautions about—and why they deserve a closer look: NSAIDs (e.g., Ibuprofen, Naproxen) Over-the-counter painkillers like ibuprofen and naproxen are go-to solutions for headaches, joint pain, and inflammation. But when used frequently or in high doses, they can raise blood pressure, cause fluid retention, and even lead to heart failure, especially in individuals with existing cardiovascular issues. Certain chemotherapy drugs (e.g., Doxorubicin, Trastuzumab) Some meds used during the chemotherapy, have been found to come at a cost to your heart. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trending in in 2025: Local network access control [Click Here] Esseps Learn More Undo Some chemotherapy agents are known to weaken the heart muscle over time, increasing the risk of heart failure. That's why many cancer patients undergo regular cardiac monitoring during and after treatment. Stimulants (e.g., Amphetamines, ADHD Medications) Medications prescribed for ADHD and narcolepsy, such as amphetamines , can elevate heart rate and blood pressure. In some cases, they may trigger arrhythmias or even heart attacks, particularly in those with underlying heart conditions or high cardiovascular risk. Older diabetes medications (e.g., Rosiglitazone) Some earlier-generation diabetes drugs have been linked to an increased risk of heart failure. While they may help manage blood sugar, they're no longer considered first-line due to their impact on heart health. Newer options now offer better cardiovascular safety, so it's worth discussing alternatives with your doctor. Decongestants Decongestants (e.g., Pseudoephedrine)found in many cold and flu medications, work by narrowing blood vessels to relieve nasal congestion. However, they can also spike blood pressure and disturb heart rhythms. Thus if you are diagnosed with high blood pressure or any heart disease, it is advised to opt for these meds only after getting it approved by your doctors.
Hindustan Times
27-06-2025
- Health
- Hindustan Times
Cardiologist shares 5 common drugs that could silently harm your heart over time: ‘Know what you're taking'
Many people take medications without realising some could have hidden effects on their heart health. Cardiologist Dr Dmitry Yaranov revealed in one of his Instagram posts five common drugs that may silently harm your heart, urging awareness and caution to protect your cardiovascular well-being. Understanding these risks can help you make informed choices and discuss alternatives with your healthcare provider. (Also read: Cardiologist warns your daily cooking oil can increase the risk of heart disease, cancer, and obesity ) Common medications may harm heart health, cardiologist cautions. (Unsplash) 'As a cardiologist, I see how some commonly used medications can silently damage your heart,' wrote Dr Dmitry in his caption. Here are five to watch out for: 1. NSAIDs (e.g., Ibuprofen, Naproxen) These common over-the-counter painkillers might seem harmless, but regular use can raise blood pressure, cause fluid retention, and in some cases, even lead to heart failure, especially with long-term use or in those with pre-existing conditions. 2. Certain chemotherapy drugs (e.g., Doxorubicin, Trastuzumab) While essential for treating cancer, some chemotherapy agents can weaken the heart muscle over time, increasing the risk of heart failure. Patients undergoing treatment often require regular cardiac monitoring. 3. Stimulants (e.g., Amphetamines, ADHD medications) Used to treat conditions like ADHD, these medications can increase heart rate and blood pressure, raising the risk of arrhythmias and, in rare cases, heart attacks, particularly in people with heart disease. 4. Diabetes drugs (e.g., Rosiglitazone) Some older diabetes medications have been linked to a heightened risk of heart failure. Many experts now recommend newer alternatives that offer better heart safety. Always consult your doctor before switching. 5. Decongestants (e.g., Pseudoephedrine) Common in cold and flu remedies, these drugs can spike blood pressure and may trigger irregular heart rhythms, posing a risk for those with high blood pressure or heart disease. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Yahoo
24-06-2025
- Health
- Yahoo
Thermosome Reports Encouraging Clinical Data of THE001 in Advanced Soft Tissue Sarcomas
Heat-triggered release mechanism unequivocally confirmed Favorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful progression-free survival (PFS) One participant with previously unresectable disease in DL2 underwent surgery, indicating no vital tumor cells in the target lesion Munich, Germany – June 24, 2025 – Thermosome GmbH, a clinical-stage drug development company focused on targeted tumor therapies, today announced new, encouraging data from its ongoing Phase I clinical trial evaluating its lead compound THE001 (DPPG2-TSL-DOX) in combination with regional hyperthermia (RHT) for the treatment of soft tissue sarcomas (STS). The Phase I study is assessing the safety, pharmacokinetics (PK), and preliminary efficacy of THE001 + RHT in participants with locally advanced unresectable or metastatic STS, who have exhausted all prior treatment options, including standard doxorubicin (DOX). Despite the early stage of development and a small number of participants, signs of meaningful clinical activity have emerged. Among the heavily pre-treated participants – including patients pre-treated with DOX – the median progression-free survival (PFS) following treatment with THE001 + RHT reached 4.5 months across both dose levels (20 and 40 mg/m²). This exceeds the typical median PFS of 2.7 to 3.5 months observed with first-line DOX therapy in treatment-naïve patients at DOX doses of 75 mg/m2, i.e., 2-4x higher than doses of THE001 applied in the Phase I setting. At dose level 2 (40 mg/m²), the mean PFS reached 7.1 months. Two out of three participants in this dose level achieved a partial response (PR) according to Choi criteria and completed the maximum extended treatment phase of 12 cycles (~8.3 months). Notably, one participant whose tumor was initially considered unresectable, could undergo surgical resection at the end of the extended study treatment. This participant showed a tumor shrinkage of -16% in the sum of target lesions, a partial response according to Choi criteria and no vital tumor cells in the resected target lesion. Across dose levels 1 and 2, THE001 + RHT demonstrated a favorable safety profile. There were no dose-limiting toxicities or high-grade treatment-related adverse events that led to treatment discontinuation, underscoring the good tolerability of THE001 in combination with RHT. 'These findings not only provide consistent proof of the galenic concept of heat-triggered, largely complete DOX release from THE001, but also demonstrate clinical benefit in a highly challenging patient population,' said Dr. Frank Hermann, Chief Medical Officer of Thermosome. 'We are particularly encouraged by the results of one participant who underwent resection after 12 full treatment cycles with THE001 and regional hyperthermia with no vital tumor cells found in the resected target lesion. These results clearly support future exploration in the neoadjuvant setting.' Alexander Eggermont, Professor of Clinical and Translational Immunotherapy, University Medical Center, Utrecht, and a member of Thermosome´s Clinical Advisory Board, commented: 'The Phase I data of THE001, a thermosensitive liposomal DOX, and regional hyperthermia in heavily pre-treated DOX-experienced soft tissue sarcoma patients, particularly from dose level 2, are very encouraging. These results demonstrate the clinical potential of this highly innovative approach and provide the necessary foundation for transitioning into Phase II proof-of-concept development. I am excited to support this important work and look forward to advancing this promising therapy, which has the potential to significantly improve outcomes for patients with soft tissue sarcoma, particularly in the neoadjuvant setting.' 'It is exciting to see the promising results of THE001 combined with regional hyperthermia, demonstrating strong potential to address the high unmet need for better treatments for soft tissue sarcoma,' added Prof. Shreyaskumar Patel, the Robert R. Herring Distinguished Professor of Medicine and Medical Director of the Sarcoma Center at The University of Texas MD Anderson Cancer Center, Houston Texas, and a member of Thermosome's Clinical Advisory Board. 'Expansion into Phase II, also including the U.S., would offer a much-needed validation of this new therapeutic strategy for patients with STS. I look forward to supporting the advancement of this innovative treatment option to improve outcomes for patients here in the U.S. and globally on the back of the orphan drug designation granted by the FDA.' Considering supportive feedback from the German Federal Institute for Drugs and Medical Devices (BfArM) on the development of THE001 + RHT in the neoadjuvant setting, the available data from last-line participants are intended to support further development in the neoadjuvant setting. ### About Thermosome Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentration and improved tumor penetration to achieve improved clinical treatment efficacy. The first clinical indication for its lead drug candidate THE001 is soft tissue sarcoma, where the Company aims to improve the current standard of care (free doxorubicin). Thermosome's approach enables targeted tumor treatment independent of specific molecular targets and covers patient populations across all chemo-sensitive tumor subtypes. More information: About THE001 Thermosome's clinical-stage lead drug candidate THE001 is a thermosensitive liposomal formulation of the chemotherapeutic drug doxorubicin (DPPG2-TSL-DOX). It has a different mode of action than conventional liposomes. Thermosome's technology enables intravascular drug release initiated by a mild heat trigger using clinically established hyperthermia devices. This results in up to 15-fold higher local drug concentrations in the tumor and aims to improve clinical treatment efficacy by creating a local boost at the desired site of action. These high local concentrations, which also reach less well perfused areas, are intended to overcome drug resistance. This effect cannot be achieved by administration of conventional doxorubicin due to systemic toxicity. Thermosome intends to further enhance treatment efficacy through an additive immune response induced by regional hyperthermia. THE001 has potential for further development in other anthracycline-sensitive solid tumors, such as breast, bladder, and ovarian cancer. THE001 has been granted Orphan Drug Designation for STS in Europe and the United States. About the Phase I Study The Phase I, open-label, interventional dose-escalation trial enrolling patients with (including DOX-) pre-treated locally advanced unresectable or metastatic STS (NCT05858710) is being conducted at two German clinical sites testing THE001 at various different dose levels in initially up to 6 cycles every 3 weeks with option to extend to up to 12 cycles in participants with at least disease control. Both completed dose level (20 mg/m² and 40 mg/m²) were well tolerated and declared safe by the independent data safety monitoring board (DSMB). Primary endpoints of the study are the safety and tolerability of THE001 and the determination of the maximum tolerated dose. A secondary objective is the evaluation of anti-tumor activity. Initial clinical data were presented at the CTOS 2024 Annual Meeting (link). About Soft Tissue Sarcomas (STS) STS is an atypical tumor with a patient population that includes many young patients. Locally advanced STS (LA-STS) are large invasive tumors that are difficult or impossible to resect. Neoadjuvant therapy is used to shrink these tumors preoperatively to allow tumor surgery with curative intent. Free doxorubicin in combination with ifosfamide or dacarbazine has been the gold standard for neoadjuvant therapy of all chemo-sensitive LA-STS for several decades. Guidelines also recommend combining DOX-based therapy with regional hyperthermia. However, with response rates of less than 30%, there is a significant unmet need for improved treatment options. Soft tissue sarcomas occur in more than 50 different subtypes that do not share a common driver mutation, making biologic targeting more difficult than physically controlled targeting with the most active agent. Company ContactThermosome GmbHAm Klopferspitz 1982152 Planegg/Martinsried (Germany)Phone: +49 89 7167760 31media@ Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth, Managing Partnersinfo@ +49 40 88 16 59 64 / +49 30 23 63 27 68Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
